Table 1 Patient and disease characteristics (N = 142)
Number | Percent | |
|---|---|---|
Age at start of anti-PD-1/PD-L1 therapy | ||
< 60 | 58 | 40.8 |
≥ 60 | 84 | 59.2 |
Smoker | ||
No | 69 | 48.6 |
Yes | 72 | 50.7 |
Unknown | 1 | 0.7 |
Gender | ||
Female | 41 | 28.9 |
Male | 101 | 71.1 |
Histology | ||
Clear cell RCC | 120 | 84.5 |
Non-clear cell RCC | 22 | 15.5 |
Presence of Sarcomatoid | ||
No | 119 | 83.8 |
Yes | 22 | 15.5 |
Unknown | 1 | 0.7 |
Presence of Rhabdoid | ||
No | 134 | 94.4 |
Yes | 6 | 4.2 |
Unknown | 2 | 1.4 |
IMDC risk group at start of anti-PD-1/PD-L1 therapy | ||
Favorable | 26 | 18.3 |
Intermediate | 85 | 59.9 |
Poor | 31 | 21.8 |
Line of therapy | ||
1 | 62 | 43.7 |
2 | 37 | 26.1 |
≥ 3 | 43 | 30.3 |
Type of anti-PD-1/PD-L1 therapy | ||
Monotherapy | 76 | 53.5 |
Combination therapy PD-L1 + VEGF targeted therapy (n = 46) PD-1 + VEGF-targeted therapy (n = 9) PD-1 + CTLA-4 (n = 7) PD-1 + other (n = 4) | 66 | 46.5 |
Median | range | |
NLR - baseline | 3.9 | 1.3–42.4 |
NLR - week 6 | 4.1 | 1.1–96.4 |